#TDOC

Teladoc and Recursion Pharmaceuticals Face Dim Outlooks Amid Growth Struggles

Investors should avoid Teladoc and Recursion Pharmaceuticals as both companies grapple with declining revenue, stiff competition, and unproven business models in a…